San Francisco, CA · Founded 2018 · Privately Held (backing)
Developer of allogeneic cellular immunotherapies designed for advancing cancer treatment. ImmuneBridge is based in San Francisco, CA and was founded in 2018. Its last reported valuation was $25 million in Jan 2023. It has raised $19.7 million across 2 recorded rounds; the latest was a $5.6 million early-stage round in Mar 2025.
Last reported valuation
$25.0M
Oct 2026
Priced at
—
Total raised
$19.7M
Last round
Early Stage VC
Mar 2025
Team — not yet on record
No current team members for ImmuneBridge are on record yet. People surface from round filings, company disclosures, and coverage sessions.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of ImmuneBridge with a free account
·The complete investor list: 16 names
·Watch ImmuneBridge: the Monday email on marks, rounds and moves
